The FDA has started a priority review of MSD's Keytruda as neoadjuvant and adjuvant treatment of locally advanced head and neck squamous cell carcinoma (HNSCC), with a decision due by 23rd June.

In particular, some clinicians are concerned that aspirin therapy might increase risk for intracranial hemorrhage among elders who fall and suffer head injuries. To determine whether this concern ...

The latest news and headlines from Yahoo News. Get breaking news stories and in-depth coverage with videos and photos.